| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Jefferies analyst Keith Devas maintains Kenvue (NYSE:KVUE) with a Buy and lowers the price target from $25 to $23.
https://truthsocial.com/@realDonaldTrump/115442316583935494
-CNBC Interview
https://www.bloomberg.com/news/articles/2025-10-20/tylenol-autism-warning-should-be-rejected-kenvue-tells-us-regulators?embedde...
https://www.reuters.com/sustainability/boards-policy-regulation/jj-faces-first-uk-lawsuits-alleging-its-baby-powder-caused-canc...
Johnson & Johnson faces 3,000 UK lawsuits alleging asbestos-contaminated talcum powder caused cancer and concealed risks fo...
Frontier AI company Albert Invent today announced a strategic partnership with Kenvue Inc. (NYSE:KVUE), maker of consumer healt...